Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.7653-0.0007 (-0.09%)
At close: 04:00PM EST
0.7700 +0.00 (+0.61%)
After hours: 07:55PM EST
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

    SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), today announces financial results for the fiscal quarter ended September 30, 2022, and provides an update on recent company developments. Atossa is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments. Key developments from Q3 2022 and to date incl

  • GlobeNewswire

    Atossa Therapeutics, Inc. to Acquire Stake in Privately Held Dynamic Cell Therapies as Part of Overall CAR-T Strategy

    SEATTLE, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), announces today that it is investing in privately-held developer of CAR-T therapies, Dynamic Cell Therapies, Inc. (DCT). Atossa is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments. “This investment in DCT is an important step in pursuing our st

  • GlobeNewswire

    Atossa Therapeutics, Inc. Announces Appointment of Pharma Industry Veteran Richard Graydon, M.D., Ph.D.

    Oversaw FDA approval of CAR-T/CAR-NK cell therapy, ADCs, and small molecule/targeted therapies for hematology-oncology diseasesSEATTLE, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology, with a current focus on breast cancer and adjunctive treatments for cancer radiotherapy, announces today that it has retained Richard Graydon, M.D.,

Advertisement
Advertisement